Biological drugs anti-TNF monoclonal antibodies are used in the treatment of various autoimmune inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis. Important in the treatment of all diseases, adherence has a special significance in the treatment of these diseases, since poor patient adherence can lead to irreversible damage to the affected structures. The aim of this specialized paper is to determine the level of adherence of patients on anti-TNF monoclonal antibody therapy by reviewing the available and relevant literature, to investigate factors affecting non-adherence, and to assess the possible role of pharmacists in improving adherence. During the preparation of this work, the PubMed database, professional literature, official websites of the European and Croatian Agency for Medicines and Medical Devices (EMA, HALMED) and other available sources were searched. Based on the results of published studies, it can be concluded that the level of adherence of patients to anti-TNFmonoclonal antibodies is very high and that these patients have an improvement in their quality of life, which also has an impact on the overall reduction of costsin the healthcare system, since there is no additional treatment and associated new costs. Factors that reduce adherence are patients' negative beliefs about the effectiveness of treatment and side effects of therapy. Since a large part of anti-TNF monoclonal antibodies is issued by prescription, the advisory role of public pharmacists is important and can contribute to better patient adherence.